129355-79-9

Upstream product

• 129355-78-8 4'-(cyclopropylcarbonyl)-N-methylacetanilide 

Downstream Products

• 129355-80-2 4-<4-(p-chlorophenyl)-4-hydroxypiperidino>-4'-(N-methylacetamido)butyrophenone 
• 129355-85-7 4-<4-<4-(p-chlorophenyl)-4-hydroxypiperidino>-1-hydroxybutyl>-N-(3-methoxycarbopropionyl)-N-methylaniline 
• 129355-82-4 4-<4-(p-chlorophenyl)-4-hydroxypiperidino>-4'-butyrophenone 
• 129355-86-8 4-<4-<4-(p-chlorophenyl)-4-hydroxypiperidino>-1-hydroxybutyl>-N-(3-carboxypropionyl)-N-methylaniline 
• 129355-81-3 4-<4-(p-chlorophenyl)-4-hydroxypiperidino>-4'-(N-methylamino)butyrophenone 

Relevant academic research and scientific papers

Direct radioimmunoassay for haloperidol in human serum

A direct radioimmunoassay for the accurate determination of haloperidol in human serum has been developed. Based on recent information about the metabolism of haloperidol, a new haloperidol hapten, in which a (3-carboxypropionyl)methylamino group was attached as a bridge in the place of fluorine atom, was synthesized and coupled to bovine serum albumin through the bridge to provide a new immunogen. Guinea pigs were used for the immunization. Since the antisera obtained by the new immunogen still cross reacted >10% with reduced haloperidol, the immunological tolerance to reduced haloperidol was induced by administration of a copolymer of D-glutamic and and D-lysine linked with reduced haloperidol. This gave an antiserum in guinea pigs which was highly specific for unchanged haloperidol with negligible cross reactivity (≤1.0%) to any haloperidol metabolites including the newly found ones. With the newly developed antiserum and [3H]haloperidol, serum haloperidol levels can be determined over the concentration range from 0.3 to 20 ng/mL, using 0.1 mL of human serum, without an extraction procedure.